Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Priti Hegde

Showing results (11-20 of 30) with videos related to

Pageof 3
Sort By:
The Oncologist|February 14, 2018
Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First-Line Nonsquamous Non-Small Cell Lung CancerJoachim von Pawel, David R Spigel, Thomas Ervin, et al.
Plos One|December 31, 2021
Transcriptomic profiling of adjuvant colorectal cancer identifies three key prognostic biological processes and a disease specific role for granzyme BAnneleen Daemen, Akshata R Udyavar, Thomas Sandmann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2014
Phase I dose-escalation study of onartuzumab as a single agent and in combination with bevacizumab in patients with advanced solid malignanciesRavi Salgia, Premal Patel, John Bothos, et al.
The Oncologist|June 24, 2023
A Novel HRD Signature Is Predictive of FOLFIRINOX Benefit in Metastatic Pancreatic CancerKuei-Ting Chen, Russell Madison, Jay Moore, et al.
Plos One|September 25, 2020
Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor originRyan Woodhouse, Meijuan Li, Jason Hughes, et al.
Frontiers in Immunology|September 26, 2022
Case report: A persistently expanded T cell response in an exceptional responder to radiation and atezolizumab for metastatic non-small cell lung cancerDavid G Coffey, Yuexin Xu, Andrea M H Towlerton, et al.
The Oncologist|November 7, 2022
Genomic Profiling Reveals Differences in Primary Central Nervous System Lymphoma and Large B-Cell Lymphoma, With Subtyping Suggesting Sensitivity to BTK InhibitionEric A Severson, James Haberberger, Amanda Hemmerich, et al.
Nature Communications|November 5, 2020
Integrated digital pathology and transcriptome analysis identifies molecular mediators of T-cell exclusion in ovarian cancerMélanie Desbois, Akshata R Udyavar, Lisa Ryner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 2015
Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio TrialThomas Sandmann, Richard Bourgon, Josep Garcia, et al.
The Oncologist|March 26, 2014
Profiling cancer gene mutations in clinical formalin-fixed, paraffin-embedded colorectal tumor specimens using targeted next-generation sequencingLiangxuan Zhang, Liangjing Chen, Sachin Sah, et al.
Pageof 3

Showing results (11-20 of 30) with videos related to

Sort By:
Pageof 3
The Oncologist|February 14, 2018
Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First-Line Nonsquamous Non-Small Cell Lung CancerJoachim von Pawel, David R Spigel, Thomas Ervin, et al.
Plos One|December 31, 2021
Transcriptomic profiling of adjuvant colorectal cancer identifies three key prognostic biological processes and a disease specific role for granzyme BAnneleen Daemen, Akshata R Udyavar, Thomas Sandmann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2014
Phase I dose-escalation study of onartuzumab as a single agent and in combination with bevacizumab in patients with advanced solid malignanciesRavi Salgia, Premal Patel, John Bothos, et al.
The Oncologist|June 24, 2023
A Novel HRD Signature Is Predictive of FOLFIRINOX Benefit in Metastatic Pancreatic CancerKuei-Ting Chen, Russell Madison, Jay Moore, et al.
Plos One|September 25, 2020
Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor originRyan Woodhouse, Meijuan Li, Jason Hughes, et al.
Frontiers in Immunology|September 26, 2022
Case report: A persistently expanded T cell response in an exceptional responder to radiation and atezolizumab for metastatic non-small cell lung cancerDavid G Coffey, Yuexin Xu, Andrea M H Towlerton, et al.
The Oncologist|November 7, 2022
Genomic Profiling Reveals Differences in Primary Central Nervous System Lymphoma and Large B-Cell Lymphoma, With Subtyping Suggesting Sensitivity to BTK InhibitionEric A Severson, James Haberberger, Amanda Hemmerich, et al.
Nature Communications|November 5, 2020
Integrated digital pathology and transcriptome analysis identifies molecular mediators of T-cell exclusion in ovarian cancerMélanie Desbois, Akshata R Udyavar, Lisa Ryner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 2015
Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio TrialThomas Sandmann, Richard Bourgon, Josep Garcia, et al.
The Oncologist|March 26, 2014
Profiling cancer gene mutations in clinical formalin-fixed, paraffin-embedded colorectal tumor specimens using targeted next-generation sequencingLiangxuan Zhang, Liangjing Chen, Sachin Sah, et al.
Pageof 3